Drug
Sage 324
Sage 324: highest development phase Phase 2/3, developed by Sage Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Sage Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAGE-324 NCT05366751 | Phase 2/3 | Essential Tremor |
| SAGE-324 NCT05173012 | Phase 2 | Essential Tremor |
| SAGE-324 NCT04305275 | Phase 2 | Essential Tremor |
Latest
No recent events.
Follow Sage 324 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.